Marshall Wace, LLP Fulcrum Therapeutics, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $643,376 - $1 Million	107,588 Added 47.7%	333,161 $2.07 Million
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $1.87 Million - $3.35 Million	-279,529 Reduced 55.34%	225,573 $2.13 Million
Q4 2023 Feb 14, 2024	SELL	$3.18 - $6.86 $1.73 Million - $3.73 Million	-543,544 Reduced 51.83%	505,102 $3.41 Million
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $3.35 Million - $6.27 Million	1,031,246 Added 5926.7%	1,048,646 $4.66 Million
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $234,135 - $393,680	-103,600 Reduced 85.62%	17,400 $57,000
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $298,491 - $1.48 Million	105,474 Added 679.34%	121,000 $344,000
Q4 2022 Feb 14, 2023	SELL	$5.01 - $8.35 $22,990 - $38,318	-4,589 Reduced 22.81%	15,526 $113,000
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $98,965 - $183,046	20,115 New	20,115 $162,000
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $134,589 - $319,582	-13,513 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $1.93 Million - $3.93 Million	-138,176 Reduced 91.09%	13,513 $239,000
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $1.1 Million - $4.7 Million	151,689 New	151,689 $4.28 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.